Esther JuliÃ¡n

List of Publications by Year
in descending order

59	1,433	430874 18	361022 35
papers	citations	h-index	g-index

64	64	64	1922
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-Î³/IL-17 release in bladder cancer treatment. OncoImmunology, 2022, 11, 2051845.	4.6	3
2	BCG Substrains Change Their Outermost Surface as a Function of Growth Media. Vaccines, 2022, 10, 40.	4.4	7
3	Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	12.2	9
4	Natural Killer Anti-Tumor Activity Can Be Achieved by In Vitro Incubation With Heat-Killed BCG. Frontiers in Immunology, 2021, 12, 622995.	4.8	14
5	Swarming behavior and in vivo monitoring of enzymatic nanomotors within the bladder. Science Robotics, 2021, 6, .	17.6	144
6	Analysis of the Lipid Composition of Mycobacteria by Thin Layer Chromatography. Journal of Visualized Experiments, 2021, , .	0.3	6
7	Easily applicable modifications to electroporation conditions improve the transformation efficiency rates for rough morphotypes of fast-growing mycobacteria. New Biotechnology, 2021, 63, 10-18.	4.4	4
8	Immunomagnetic Separation Improves the Detection of Mycobacteria by Paper-Based Lateral and Vertical Flow Immunochromatographic Assays. Sensors, 2021, 21, 5992.	3.8	7
9	Effects of Mycobacterium bovis Calmette et GuÃ©rin (BCG) in oncotherapy: Bladder cancer and beyond. Vaccine, 2021, 39, 7332-7340.	3.8	13
10	Each Mycobacterium Requires a Specific Culture Medium Composition for Triggering an Optimized Immunomodulatory and Antitumoral Effect. Microorganisms, 2020, 8, 734.	3.6	5
11	Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers. Cancers, 2020, 12, 1802.	3.7	14
12	Bacillus Calmette-GuÃ©rin (BCG) Therapy for Bladder Cancer: An Update . ImmunoTargets and Therapy, 2020, Volume 9, 1-11.	5.8	116
13	Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment. Vaccines, 2020, 8, 198.	4.4	9
14	Cording Mycobacterium tuberculosis Bacilli Have a Key Role in the Progression towards Active Tuberculosis, Which is Stopped by Previous Immune Response. Microorganisms, 2020, 8, 228.	3.6	7
15	Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer. Translational Research, 2018, 197, 32-42.	5.0	9
16	Molecule confirmation and structure characterization of pentatriacontatrienyl mycolate in Mycobacterium smegmatis. Chemistry and Physics of Lipids, 2018, 212, 138-143.	3.2	4
17	Pentafluorosulfanyl-containing Triclocarban Analogs with Potent Antimicrobial Activity. Molecules, 2018, 23, 2853.	3.8	25
18	Hydroxylamine Derivatives as a New Paradigm in the Search of Antibacterial Agents. ACS Omega, 2018, 3, 17057-17069.	3.5	10

#	Article	IF	Citations
19	Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice. Scientific Reports, 2018, 8, 15102.	3.3	11
20	Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers. , 2018, , .		2
21	A single point mutation in class III ribonucleotide reductase promoter renders Pseudomonas aeruginosa PAO1 inefficient for anaerobic growth and infection. Scientific Reports, 2017, 7, 13350.	3.3	13
22	Trehalose Polyphleates, External Cell Wall Lipids in Mycobacterium abscessus, Are Associated with the Formation of Clumps with Cording Morphology, Which Have Been Associated with Virulence. Frontiers in Microbiology, 2017, 8, 1402.	3.5	25
23	Mycobacteria Clumping Increase Their Capacity to Damage Macrophages. Frontiers in Microbiology, 2016, 7, 1562.	3.5	60
24	Draft Genome Sequence of Mycobacterium brumae ATCC 51384. Genome Announcements, 2016, 4, .	0.8	4
25	Magneto-actuated immunoassay for the detection of Mycobacterium fortuitum in hemodialysis water. Talanta, 2016, 153, 38-44.	5.5	10
26	Nonpathogenic Mycobacterium brumae Inhibits Bladder Cancer Growth In Vitro, Ex Vivo, and In Vivo. European Urology Focus, 2016, 2, 67-76.	3.1	22
27	Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment. Scientific Reports, 2016, 6, 27232.	3.3	15
28	Î³ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria. Journal of Urology, 2016, 195, 198-205.	0.4	13
29	Draft Genome Sequences of Mycobacterium setense Type Strain DSM-45070 and the Nonpathogenic Strain Manresensis, Isolated from the Bank of the Cardener River in Manresa, Catalonia, Spain. Genome Announcements, 2015, 3, .	0.8	11
30	Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections. Journal of Controlled Release, 2015, 209, 150-158.	9.9	182
31	Antibacterial activity of novel benzopolycyclic amines. Bioorganic and Medicinal Chemistry, 2015, 23, 290-296.	3.0	7
32	Methyl-Hydroxylamine as an Efficacious Antibacterial Agent That Targets the Ribonucleotide Reductase Enzyme. PLoS ONE, 2015, 10, e0122049.	2.5	12
33	Killed but Metabolically Active Mycobacterium bovis bacillus Calmette-GuÃ©rin Retains the Antitumor Ability of Live bacillus Calmette-GuÃ©rin. Journal of Urology, 2014, 191, 1422-1428.	0.4	26
34	Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-GuÃ©rin Substrains. Journal of Urology, 2013, 189, 711-718.	0.4	48
35	Cording, a Virulence-related Characteristic of Mycobacteria, Analysis Using SEM. Microscopy and Microanalysis, 2012, 18, 21-22.	0.4	0
36	Cyclopropanation of Î±-mycolic acids is not required for cording in Mycobacterium brumae and Mycobacterium fallax. Microbiology (United Kingdom), 2012, 158, 1615-1621.	1.8	7

#	Article	IF	Citations
37	Revisited mycolic acid pattern of Mycobacterium confluentis using thin-layer chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2821-2826.	2.3	7
38	Prevalence and Concentration of Non-tuberculous Mycobacteria in Cooling Towers by Means of Quantitative PCR: A Prospective Study. Current Microbiology, 2011, 62, 313-319.	2.2	14
39	Misdiagnosis of Mycobacterium brumae Infection. Journal of Clinical Microbiology, 2011, 49, 1190-1192.	3.9	4
40	Demonstration of Cord Formation by Rough Mycobacterium abscessus Variants: Implications for the Clinical Microbiology Laboratory. Journal of Clinical Microbiology, 2011, 49, 2293-2295.	3.9	39
41	Microscopic Cords, a Virulence-Related Characteristic of Mycobacterium tuberculosis , Are Also Present in Nonpathogenic Mycobacteria. Journal of Bacteriology, 2010, 192, 1751-1760.	2.2	80
42	Increased levels of immunological markers in the respiratory tract but not in serum correlate with active pulmonary mycobacterial infection in mice. Clinical Microbiology and Infection, 2009, 15, 777-786.	6.0	4
43	Surface Spreading Motility Shown by a Group of Phylogenetically Related, Rapidly Growing Pigmented Mycobacteria Suggests that Motility Is a Common Property of Mycobacterial Species but Is Restricted to Smooth Colonies. Journal of Bacteriology, 2008, 190, 6894-6902.	2.2	33
44	Impaired Gamma Interferon Response to Mycobacterium vaccae Antigens in Patients with Cavitary Pulmonary Tuberculosis. Vaccine Journal, 2008, 15, 1485-1488.	3.1	2
45	Mice with Pulmonary Tuberculosis Treated with Mycobacterium vaccae Develop Strikingly Enhanced Recall Gamma Interferon Responses to M. vaccae Cell Wall Skeleton. Vaccine Journal, 2008, 15, 893-896.	3.1	9
46	TLR2 but not TLR4 Signalling is Critically Involved in the Inhibition of IFN-?-induced Killing of Mycobacteria by Murine Macrophages. Scandinavian Journal of Immunology, 2007, 65, 148-157.	2.7	40
47	Occurrence of an antigenic triacyl trehalose in clinical isolates and reference strains of Mycobacterium tuberculosis. FEMS Microbiology Letters, 2006, 157, 251-259.	1.8	21
48	Determinant role for Toll-like receptor signalling in acute mycobacterial infection in the respiratory tract. Microbes and Infection, 2006, 8, 1790-1800.	1.9	36
49	The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production. Antonie Van Leeuwenhoek, 2006, 90, 93-108.	1.7	12
50	Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis. Microbes and Infection, 2006, 8, 183-190.	1.9	36
51	Exposure to Mycobacteria Primes the Immune System for Evolutionarily Diverse Heat Shock Proteins. Infection and Immunity, 2005, 73, 7687-7696.	2.2	13
52	Comparison of Antibody Responses to a Potential Combination of Specific Glycolipids and Proteins for Test Sensitivity Improvement in Tuberculosis Serodiagnosis. Vaccine Journal, 2004, 11, 70-76.	2.6	41
53	Serodiagnosis of Tuberculosis: Comparison of Immunoglobulin A (IgA) Response to Sulfolipid I with IgG and IgM Responses to 2,3-Diacyltrehalose, 2,3,6-Triacyltrehalose, and Cord Factor Antigens. Journal of Clinical Microbiology, 2002, 40, 3782-3788.	3.9	42
54	Production of Antibodies against Glycolipids from the Mycobacterium tuberculosis Cell Wall in Aerosol Murine Models of Tuberculosis. Scandinavian Journal of Immunology, 2002, 55, 639-645.	2.7	19

#	Article	IF	Citations
55	An ELISA for five glycolipids from the cell wall of Mycobacterium tuberculosis:. Journal of Immunological Methods, 2001, 251, 21-30.	1.4	40
56	Seroreactive species-specific lipooligosaccharides of Mycobacterium mucogenicum sp. nov. (formerly) Tj ETQq0 0 0 rgBT /Overlock 10 T (United Kingdom), 1998, 144, 137-148.	1.8	21
57	Distribution of surface-exposed antigenic glycolipids in recent clinical isolates of Mycobacterium tuberculosis. Research in Microbiology, 1997, 148, 405-412.	2.1	12
58	Easy differentiation of Mycobacterium mucogenicum from other species of the Mycobacterium fortuitum complex by thin-layer and gas chromatography of fatty esters and alcohols. Biomedical Applications, 1997, 689, 341-347.	1.7	10
59	Detection of lipoarabinomannan antibodies in patients with newly acquired tuberculosis and patients with relapse tuberculosis. Journal of Clinical Microbiology, 1997, 35, 2663-2664.	3.9	19